Dong-A ST Collaborates with Israeli Biotech Company on RNA-Based Gene Therapy Research
Development of RNA New Drug for Fibrosis Disease
Joint Research with Biotech Company Underway
Dong-A ST announced on the 10th that it has signed a business agreement with Israeli biotech company 'Eleven Therapeutics' for the development of RNA-based gene therapy at the JP Morgan Healthcare Conference (JPMHC) held in San Francisco, USA.
The two companies plan to conduct joint research to discover RNA therapeutics for fibrotic diseases using Eleven's 'TERA' platform technology. The TERA platform is a technology that decodes the structure-activity relationship of RNA chemical modifications using AI (artificial intelligence) and ML (machine learning) technologies, and is utilized to discover optimal xRNA drugs.
Dong-A ST has selected gene therapy as one of its next-generation core fields and continues efforts to expand its research and development capabilities from its existing strength in synthetic new drugs to the gene therapy field.
Founded in 2020, Eleven is an Israeli biotech company developing xRNA by combining combinatorial chemistry and synthetic biology technologies with artificial intelligence and machine learning. The Bill & Melinda Gates Foundation invested $9 million, and Eleven has established a joint research partnership with Novo Nordisk for the development of RNA therapeutics for cardiovascular diseases. Currently, it has research centers and offices not only in Israel but also in the United States and the United Kingdom.
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Man in His 40s Who Kept Girlfriend's Body for a Year After Murder Sentenced to 30 Years in Prison Again on Appeal
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
Jae-Hong Park, Head of R&D at Dong-A ST, said, "Through collaboration with Eleven, which possesses excellent technology, we have taken a step closer to developing innovative RNA therapeutics," adding, "We will strive to transform Dong-A ST into a company centered on gene and cell therapies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
